Catalysts / ALDX
Upcoming FDA decisions and readouts we track for Aldeyra Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Aldeyra Therapeutics (ALDX, listed on Nasdaq). It concerns Reproxalap (Dry eye disease).
First on the list: the Regulatory milestone for Reproxalap (Dry eye disease), guided by the company to Q4 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.
Background reading: Why catalyst windows like "H2 2026" are vague, and how they narrow.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics ALDX · Nasdaq | Reproxalap | Dry eye disease | Q4 2026 company guidance |
Regulatory milestone | Verified | 8-K exhibit 99.2 ↗ | Yes |
FreeBioList